Literature DB >> 8415579

Making tissue-type plasminogen activator more fibrin specific.

N F Paoni1, A M Chow, L C Peña, B A Keyt, M J Zoller, W F Bennett.   

Abstract

The fibrin specificity of tissue-type plasminogen activator can be increased by mutagenesis within at least four sites in the protease domain. These sites include residue I276, the new N-terminus formed by conversion to a two-chain structure, residues on either side of the active site cleft, KHRR 296-299 or DDD 364-366, a charged surface involved in fibrin interactions, which includes residues H432, R434, D460, R462 and a loop structure, PQANL 466-470, near the fibrin-binding patch. Variants with mutations at any of these sites have low fibrinogen-stimulated activity, whereas fibrin-stimulated activity is at least normal. Kinetic analysis reveals that mutations at these positions reduce the kcat in the presence of fibrinogen, but leave the molecules with normal kinetic constants in the presence of fibrin. A significant exception is found at positions 296-299, where the presence of fibrin manifests significant increases in both kcat and Km. Combinations of mutations at these sites appear to be additive with respect to fibrin specificity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415579     DOI: 10.1093/protein/6.5.529

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  5 in total

1.  A faster-acting and more potent form of tissue plasminogen activator.

Authors:  B A Keyt; N F Paoni; C J Refino; L Berleau; H Nguyen; A Chow; J Lai; L Peña; C Pater; J Ogez
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

2.  Role of P225 and the C136-C201 disulfide bond in tissue plasminogen activator.

Authors:  A Vindigni; E Di Cera
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

Review 3.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

4.  Asn and asn: critical residues for in vitro biological activity of reteplase.

Authors:  Naganath Mandi; Kalyana R Sundaram; Sunil K Tandra; Suman Bandyopadhyay; Sriram Padmanabhan
Journal:  Adv Hematol       Date:  2010-06-21

Review 5.  Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review.

Authors:  Annie Zhu; Phavalan Rajendram; Eric Tseng; Shelagh B Coutts; Amy Y X Yu
Journal:  Res Pract Thromb Haemost       Date:  2022-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.